Illumina, Inc. $ILMN Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 40.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 117,317 shares of the life sciences company’s stock after acquiring an additional 33,514 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Illumina were worth $14,460,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of ILMN. HighPoint Advisor Group LLC increased its stake in shares of Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after purchasing an additional 80 shares in the last quarter. Meeder Advisory Services Inc. boosted its position in Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares in the last quarter. Toronto Dominion Bank boosted its position in Illumina by 0.3% during the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 96 shares during the period. Finally, Venturi Wealth Management LLC grew its holdings in Illumina by 4.2% in the fourth quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock valued at $323,000 after purchasing an additional 99 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

NASDAQ:ILMN opened at $205.10 on Monday. The stock has a 50 day moving average of $176.70 and a two-hundred day moving average of $147.25. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $205.93. The firm has a market cap of $31.03 billion, a P/E ratio of 38.26, a price-to-earnings-growth ratio of 2.94 and a beta of 1.47. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts expect that Illumina, Inc. will post 5.37 earnings per share for the current fiscal year.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the transaction, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. This trade represents a 2.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock worth $155,710,908 in the last quarter. 2.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ILMN. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday. Citigroup lifted their price target on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Barclays boosted their price target on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday. Finally, Stifel Nicolaus upped their price objective on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $175.47.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.